Obesity
Study Categories
NEW MACUPATIDE AND ELORALINTIDE WEIGHT LOSS STUDIES FOR PERSONS WITHOUT DIABETES
Intro: These two new Studies will investigate weight management in adult participants with Obesity or Overweight and without Diabetes.
Investigational Drug: Macupatide and Eloralintide, alone or in combination
You may qualify if you:
- are 18 to 75 years
- are overweight: we can see if your body mass index is high (BMI of ≥30 kg/m2, or ≥27 kg/m2 and <30 kg/m2, with at least one weight-related comorbidity (such as hypertension, high cholesterol or triglycerides, cardiovascular disease, obstructive sleep apnea, hyperuricemia/gout, PCOS, urinary incontinence, osteoarthritis, chronic lower back pain/knee pain, metabolic liver disease (MASLD or “fatty liver”) or chronic kidney disease)
- have an HbA1c of under 6.5%
- have not taken weight loss medications in the past 6 months
- don’t have a prior diagnosis of diabetes mellitus (except for gestational diabetes).
Goal: To assess investigational medications on weight loss in persons with obesity with or without risk factors.
NEW AMYLIN WEIGHT LOSS STUDY FOR PERSONS WITHOUT DIABETES
Intro: This AbbVie study will investigate a once-weekly weight loss medication in persons without diabetes.
Investigational Drug: long-acting Amylin
Key Eligibility Criteria:
Inclusion Criteria:
- BMI ≥ 30.0 kg/m2 at Screening or
- BMI ≥ 27.0 to < 30.0 kg/m2 with at least one of the following weight-related conditions: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or MASLD.
Exclusion Criteria:
- Hemoglobin A1c (HbA1c) ≥ 6.5% (48 mmol/mol) at screening
- Fasting glucose ≥126 mg/dL or random glucose test ≥ 200 mg/dL
- History of type 1 or type 2 diabetes mellitus
- Treatment with any medication or product used for obesity or weight management within 180 days prior to screening.
NEW ORAL RETATRUTIDE WEIGHT LOSS STUDY FOR PERSONS WITHOUT DIABETES
Intro: This Lilly study will investigate an oral weight management medication for persons without diabetes.
Investigational Drug: Oral Retatrutide, a triple hormone receptor agonist that activates the body’s receptors for GLP-1, GIP and glucagon.
You may be eligible if you:
- are 18 to 75 years
- have clinical obesity condition (that is if your body mass index is high, BMI of ≥30 kg/m2 – we will calculate for you)
- have moderate overweight condition (BMI ≥27 kg/m2) with at least one weight-related diagnosis (such as hypertension, high cholesterol or triglycerides, cardiovascular disease, obstructive sleep apnea, hyperuricemia/gout, PCOS, urinary incontinence, osteoarthritis, chronic lower back pain/knee pain, metabolic liver disease (MASLD) or “fatty liver,” or chronic kidney disease)
- have an HbA1c of under 6.5% (that is you don’t have diabetes)
- have not taken weight loss medications in the past 6 months.